Rac1 and pSTAT3 expression as pharmacodynamic markers in thiopurine-treated IBD

Open-label trial of azathioprine, mercaptopurine and tioguanine in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (3 arms), sponsored by Zuyderland. Primary endpoint: Difference in Rac1 and pSTAT3 expression and activation in leukocytes of IBD patients on thiopurines and healthy volunteers. Started Jan 2021; status: active, not recruiting.